Grifols (GIKLY) Change in Account Payables (2010 - 2020)
Grifols (GIKLY) reported Change in Account Payables of -$25.7 million for Q1 2020, up 53.91% on a YoY basis from -$16.7 million in Q2 2019, and up 67.14% quarter-over-quarter from -$78.2 million in Q4 2019.
Grifols (GIKLY) Change in Account Payables (2010 - 2020) Analysis & Trends
Grifols has reported Change in Account Payables for 10 years, with the latest figure at -$25.7 million in Q1 2020.
- For the quarter ending Q1 2020, Change in Account Payables rose 53.91% year-over-year to -$25.7 million; the trailing twelve-month figure through Mar 2020 stood at -$155.5 million (down 134.7% YoY), and the FY2025 full-year result was $109.4 million, up 253.09% from the prior year.
- Change in Account Payables for Q1 2020 stood at -$25.7 million, up from -$78.2 million in the prior quarter.
- The five-year high for Change in Account Payables was $81.5 million in Q4 2016, with the low at -$78.2 million in Q4 2019.
- Historically, Change in Account Payables has averaged -$5.2 million across 5 years, with a median of $4.2 million in 2018.
- Annual changes were most pronounced in 2016 — Change in Account Payables jumped 128.83% — and 2019, when it plunged 1957.3%.
- Grifols' Change in Account Payables stood at $81.5 million in 2016, then slumped by 40.67% to $48.3 million in 2017, then tumbled by 91.29% to $4.2 million in 2018, then sank by 1957.3% to -$78.2 million in 2019, then jumped by 67.14% to -$25.7 million in 2020.
- The last three Change in Account Payables figures came in at -$25.7 million (Q1 2020), -$78.2 million (Q4 2019), and -$55.8 million (Q1 2019), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | - |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | - |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | - |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 571.00 Mn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | -67.00 Mn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 409.00 Mn |
| 10 | Grifols | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | -25.70 Mn |
| Mar 31, 2020 | -25.70 Mn |
| Dec 31, 2019 | -78.22 Mn |
| Dec 31, 2019 | -78.22 Mn |
| Mar 31, 2019 | -55.77 Mn |
| Mar 31, 2019 | -55.77 Mn |
| Dec 31, 2018 | 4.21 Mn |
| Dec 31, 2018 | 4.21 Mn |
| Jun 30, 2018 | -22.71 Mn |
| Jun 30, 2018 | -22.71 Mn |
| Mar 31, 2018 | 8.02 Mn |
| Mar 31, 2018 | 8.02 Mn |
| Dec 31, 2017 | 48.35 Mn |
| Dec 31, 2017 | 48.35 Mn |
| Jun 30, 2017 | 34.54 Mn |
| Jun 30, 2017 | 34.54 Mn |
| Mar 31, 2017 | 19.09 Mn |
| Mar 31, 2017 | 19.09 Mn |
| Dec 31, 2016 | 81.49 Mn |
| Dec 31, 2016 | 81.49 Mn |